期刊文献+

二甲双胍与诺和灵30R联合治疗2型糖尿病的临床研究 被引量:3

下载PDF
导出
摘要 目的探讨二甲双胍与诺和灵30R联合治疗2型糖尿病的临床效果。方法选择60例患者,随机分为观察组和对照组,观察组用二甲双胍与诺和灵30R联合治疗,对照组单用诺和灵30R,比较两组疗效和血糖控制水平。结果观察组治疗总有效率为86.7%,对照组治疗总有效率为63.3%,两组比较差异显著(P<0.05);与对照组比较,观察组治疗后空腹血糖、餐后2h血糖和糖化血红蛋白均明显下降(P<0.05),血糖得到有效控制。结论二甲双胍与诺和灵30R联合治疗2型糖尿病能使患者血糖得到有效控制,提高了治疗效率,值得在临床推广应用。
出处 《中国医药指南》 2010年第8期123-124,共2页 Guide of China Medicine
  • 相关文献

参考文献4

二级参考文献15

  • 1于学满,赵晓娟.2型糖尿病患者血清抵抗素与血糖、血脂及胰岛素抵抗的关系[J].实用医学杂志,2005,21(11):1138-1140. 被引量:8
  • 2朱大龙.炎症与2型糖尿病[J].中国糖尿病杂志,2006,14(1):73-74. 被引量:58
  • 3赵振国,江渝.动脉粥样硬化中主要炎症细胞因子的作用[J].国际检验医学杂志,2006,27(10):919-920. 被引量:8
  • 4Blagat S,Gaiha M,Sharma V K,et al.A comparative evalvation of C-reactive protein as a short-term pronostic marker in severe unstable angina--a preliminary study[J].J Assoc Physicians India,2003,51(4):349-354.
  • 5Danid G,Hackam M D,Sonia S.Emerging risk factors for atherasclerotic vascular disease[J].JAMA,2003,290(7):932-939.
  • 6Bloomgarden I T.Inflammation and insulin resistance[J].Diabetes Care,2003,26(6):1922-1926.
  • 7Anderson JH, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Int Med, 1997,157:1249-1255.
  • 8Janssen MMJ, Casteleijn S, Deville W, et al. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care, 1997,20: 1870-1873.
  • 9Roach P, Strack T, Arora V, et al. Improved glyeaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Prac, 2001,55:177-182.
  • 10Roach P, Yue L, Arora V, et al. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care, 1999, 22 : 1258-1261.

共引文献96

同被引文献31

  • 1何嗣英,吴勇群.二甲双胍和格列吡嗪对胰岛素敏感指数等的影响[J].海南医学院学报,2006,12(4):336-337. 被引量:3
  • 2国家基本药物目录化学药品和生物制品(2009版基层部分).人民卫生出版社,2009.
  • 3The Clinical & Scientific Section of the Canadian Diabetes Associa- tion. Canadian Diabetes Association 2008 Clinical Practice Guide- lines for the Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes, 2009, 52: 552-553.
  • 4American Association of" Clinical Endocrinologists Medical Guide- lines for Clinical Practice. Medical guidelines for clinical practice foe developing a diabetes mellitus comprehensive care plan. AACE Dia- betes Care Plan Guidelines. Endocr Pratt, 2011, 17(SUPPL2): 1-53.
  • 5Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes A national clinical guideline.2011. Available at: http://www. sign.ac.uk.
  • 6SEMDSA. SEMDSA Guidelines for Diagnosis and Management of Type 2 Diabetes Mellitus for Primary Health Care-2009. Available at: http://www.semdsa.org.za/.
  • 7WHO. Guidelines for the prevention, management and care of dia- betes mellitus. 2006. Available at: http://www.who.int/zh/.
  • 8WHO Model List of Essential Medicines (17th list). 2011. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/index.html.
  • 9Stuart MC, Kouimtzi M, Hill SR. WHO model formulary 2008.
  • 10中国国家处方集.化学药品与生物制品卷.人民军医出版社,2010.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部